The Impact of Thoracic Radiotherapy on Advanced Small Cell Lung Cancer in the Context of Immunotherapy: A Review of Existing Evidence - Takeaways - MDSpire

The Impact of Thoracic Radiotherapy on Advanced Small Cell Lung Cancer in the Context of Immunotherapy: A Review of Existing Evidence

  • By

  • Zhipeng Li

  • Xiao Lei

  • Xingdong Guo

  • Qiduo He

  • Yanan Han

  • Pei Zhang

  • Lehui Du

  • Baolin Qu

  • April 29, 2026

  • 0 min

Share

  • 1

    Extensive-stage small cell lung cancer (ES-SCLC) has a poor prognosis, with a 2-year survival rate below 5%.

  • 2

    Chemotherapy combined with immunotherapy has become the new standard first-line treatment for ES-SCLC.

  • 3

    Thoracic radiotherapy (TRT) shows potential for improving survival outcomes in ES-SCLC when combined with chemoimmunotherapy.

  • 4

    The absolute survival benefit from immunotherapy in ES-SCLC patients remains limited, extending median overall survival by only 3 months.

  • 5

    Research is ongoing to identify optimal TRT dosing and timing, as well as predictive biomarkers for combined therapy efficacy in ES-SCLC.

Original Source(s)

The Impact of Thoracic Radiotherapy on Advanced Small Cell Lung Cancer in the Context of Immunotherapy: A Review of Existing Evidence

  • by Zhipeng Li, Xiao Lei, Xingdong Guo, Qiduo He, Yanan Han, Pei Zhang, Lehui Du, Baolin Qu

  • April 29, 2026

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications